Business / Finance

RSS

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Silence Therapeutics Plc, a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2011.

21 Sep 2011

Tokai raises $23M in Series D3 financing

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that it has raised $23 million in a Series D3 financing.

20 Sep 2011

NanoViricides acquires light industrial building for laboratory facilities and cGMP production

NanoViricides, Inc. announced that Inno-Haven LLC has completed acquisition of a light industrial building. The Company anticipates that it will be leasing a portion of this space, in the near future, for laboratory facilities and cGMP production of its nanoviricides® drug candidates against various viral diseases.

19 Sep 2011

KYTHERA closes $37.4M Series D financing

KYTHERA Biopharmaceuticals, Inc., a privately-held biotechnology company focused on the development and commercialization of products in aesthetic medicine, today announced the closing of a $37.4M Series D financing.

19 Sep 2011

Alkermes establishes business operations in Ireland

Alkermes plc today announced the establishment of its corporate operations in Ireland, with new headquarters located in Dublin. The company, including its headquarters and operations in Athlone, County Westmeath, has more than 450 employees based in Ireland and more than 1,200 employees worldwide.

19 Sep 2011

MDC Partners acquires majority stake in Concentric Pharma Advertising

MDC Partners announced today that they have acquired a majority stake in leading healthcare and pharma advertising and marketing agency, Concentric Pharma Advertising.

17 Sep 2011

Radiology Associates of North Texas extends billing services contract with Zotec Partners

Zotec Partners, an industry leader in medical billing, practice management and Radiology Information Systems (RIS) software and services, announces today it has received a multi-year contract extension from Radiology Associates of North Texas, PA, formerly Radiology Associates of Tarrant County.

17 Sep 2011

Infrared Systems International is now AquaLiv Technologies

Infrared Systems International announced it has changed its name to AquaLiv Technologies, Inc. in order to better reflect its new corporate strategy. Along with the name change the company has been issued a new symbol by FINRA of AQLV.

17 Sep 2011

Topcon Europe Medical to distribute LensAR product line in Europe

Topcon Europe Medical BV and LensAR Inc announce their intent to enter into a long term strategic cooperation. Topcon Europe Medical BV will be responsible for the distribution and marketing the LensAR product line in Europe.

17 Sep 2011

Millennium ranked fifth among best biopharmaceutical companies in the world

Millennium: The Takeda Oncology Company today announced that Science magazine has named it among the best biopharmaceutical companies in the world for the fourth consecutive year. Each year Science conducts a survey to determine the top employers in the biotechnology, biopharmaceutical, pharmaceutical and related industries worldwide.

17 Sep 2011

LifePoint Hospitals' board authorizes new $250M stock repurchase program

LifePoint Hospitals, Inc. today announced that its Board of Directors, at a regularly scheduled meeting, has authorized a new stock repurchase program that will allow for repurchases of up to $250 million of its common stock over the next 18 months. Amounts available under the Company's previously announced share repurchase program were exhausted during the current fiscal quarter.

17 Sep 2011

InNexus Biotechnology announces incentive stock options

InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announces that it has, effective August 26, 2011, granted incentive stock options to purchase an aggregate of 1,068,683 common shares without par value in the capital of the Company to certain persons who are either a director, officer, employee or consultant of the Company.

17 Sep 2011

Elan commences planned measures to reduce indebtedness

Elan Corporation, plc announced today that it has commenced planned measures to reduce its indebtedness using the cash proceeds received in connection with the combination of its EDT business with Alkermes Inc., which closed today.

17 Sep 2011

Wolters Kluwer Pharma Solutions leases 70,000-square-foot space in Phoenix

Wolters Kluwer Pharma Solutions, a leading provider of scientific information and analytics to pharmaceutical and healthcare professionals, today announced the signing of an 8-year lease on 70,000 square feet of new office space in the Biltmore Financial Center office park in Phoenix, AZ.

17 Sep 2011

Alkermes completes merger with Elan Drug Technologies

Alkermes plc and Elan Corporation, plc today announced the completion of the merger between Alkermes, Inc. and Elan Drug Technologies (EDT), the drug formulation and manufacturing business unit of Elan, following the approval of the merger by Alkermes, Inc. shareholders on Sept. 8, 2011.

17 Sep 2011

DestinationRx is now DRX

DestinationRx, Inc., a leading provider of healthcare comparison tools, technology and data, today announced a strategic decision to rename the company DRX. The change in branding is a response to the company's significant growth in the healthcare industry—from its origins in prescription drug pricing and purchasing technology to its expansion into broader drug and health plan comparison technology and data services.

17 Sep 2011

Merus applies for listing on TSX Venture Exchange

Merus Labs International Inc. reports that it has made application to list its common shares on the TSX Venture Exchange.

16 Sep 2011

General Electric establishes two new joint ventures in Russia

Today, GE expanded its position in one of the world's fastest growing markets by finalizing agreements to set up two new joint ventures in Russia which could drive $10 - $15 billion in sales. Under the new JVs, we anticipate orders of energy-efficient heavy-duty gas-fired power generation turbines with total capacity of up to 5 gigawatts of power as well as thousands of high-tech medical diagnostic units in Russia.

16 Sep 2011

Generex issues update on Antigen Express spinout

Generex Biotechnology Corporation today provided an update on the status of the previously announced spinout of its wholly-owned subsidiary, Antigen Express, Inc..

16 Sep 2011

Teva to invest in CDI for development of novel antiviral drugs

Teva Pharmaceutical Industries Ltd. announced today that it has signed a collaboration option to license and share purchase agreements to invest in Cocrystal Discovery Inc. (CDI), a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases.

16 Sep 2011